arrow
D

Daniel C. Danila

Memorial Sloan Kettering Cancer Center
H指数:46
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)

雄激素受体剪接变体7的细胞质与核定位作为预测转移性去势抵抗性前列腺癌中雄激素受体通路抑制剂获益的指标(PROPHECY试验)

2026-04-020
PRE
Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Xaluritamig,一种STEAP1 x CD3 XmAb 2+1免疫疗法,在转移性去势抵抗性前列腺癌(mCRPC)患者(pts)中的初步研究结果:来自一项I期研究剂量扩展队列的数据

2024-09-010
PRE
Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig

循环肿瘤细胞(CTC)计数和总生存期(OS)在用xaluritamig治疗的转移性去势抵抗性前列腺癌(mCRPC)男性患者中的情况

2024-09-010
PRE
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer

与前列腺癌骨活检组织成功基因组分析相关的临床、影像和技术因素

2024-08-010
PRE
Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Xaluritamig,用于转移性去势抵抗性前列腺癌的STEAP1 x CD3 XmAb 2 1免疫疗法: 首次人体研究中剂量探索的结果

2023-10-2014
OAAI
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

前列腺癌仅肿瘤测序后基于基因的验证性种系检测

2023-01-019
OA
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
2021-12-0111
OAAI
Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
2021-09-012
OA